Drugs / UB-VV400
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06743503 | Apr 2025 → May 2028 expected | large B-cell lymphoma | Nanjing IASO Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UB-VV400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06743503 ↗ |
| Route | Intravenous | “UB-VV400 monotherapy, administered IV” NCT06743503 ↗ |